Tag: HDAC

CG-200745, a HDAC Inhibitor, Induces the Accumulation of p53

Histone deacetylase (HDAC) inhibits are considered to be promising agents that can be used as treatments for cancer. CG-200745 is a novel and potent hydroxamate-based pan-HDAC inhibitor. CG-200745 has the hydroxamic acid moiety to bind zinc at the bottom of the catalytic pocket. We will introduce its anti-tumorigenic property...

SS-208 is a Selective HDAC6 Inhibitor for Melanoma

Malignant melanoma represents the most aggressive and deadliest form of cutaneous cancer. This disease possesses the characteristic of increasing incidence, high metastasis, rapid disease progression, poor prognosis, and high mortality. The latest data showed that patients with metastatic melanoma have a poor prognosis with a 5-year survival rate of...

TH34, an HDAC6/8/10 Inhibitor, Induces Caspase-Dependent Programmed Cell Death

HDAC (Histone deacetylases) are a group of proteins that act on histones. They remove acetyl groups from N-acetyl lysine amino acid on a histone. As a result, histones wrap DNA more tightly. The enzymes have opposite function to histone acetyltransferase. But, they both regulate DNA expression. HDAC is a...

SRT 2183, a Selective Sirtuin-1 Activator, Induces Growth Arrest and Apoptosis

Sirtuin-1 (SIRT1) , is an NAD+-dependent class III HDAC. Previous studies have showed SIRT1 as regulator of diverse physiological functions, including metabolic responses to caloric restriction and exercise training, circadian rhythm, DNA repair, cell survival, senescence, death, and differentiation. Furthermore, SIRT1 also is potential for SIRT1 in diabetes, cardiovascular...